First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors



Status:Recruiting
Conditions:Lung Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/17/2019
Start Date:December 14, 2016
End Date:September 2020
Contact:Holly Beever, BS, RN
Email:hbeever@toleropharma.com
Phone:210-365-9014

Use our guide to learn which trials are right for you!

A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors

TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal
phenotype associated with advanced cancers. Preclinical studies have shown promising
antitumor activity of TP-0903 as a single agent against a variety of tumor types in both in
vitro and in vivo studies.

This first-in-human Phase 1a study is conducted to identify the maximum tolerated dose (MTD)
of TP-0903 administered orally to patients with advanced solid tumors and to identify the
safety profile and Recommended Phase 2 Dose (RP2D) of TP-0903. Once the MTD has been
established, additional patients with specific tumor types (advanced solid tumors that have
progressed after achieving a best documented response of at least stable disease (ie, SD, PR,
or CR documented per iRECIST following at least 2 cycles (8 weeks) of immunotherapy, EGFR+
Non Small Cell Lung Cancer [NSCLC] and have demonstrated recent progression following a best
documented response of at least stable disease (ie, SD, PR, or CR documented per RECIST v1.1
on ≤2 lines of oral TKIs (Prior chemotherapy ± immunotherapy is allowed as long as the
patient is clearly demonstrating current progression on an EGFR TKI.), BRAF-, KRAS-, or
NRAS-mutated Colorectal Carcinoma [CRC] for whom there is no standard therapy remaining,
persistent/recurrent Ovarian Cancer who would be platinum refractory/ resistant and have had
any number of lines of prior therapy, and BRAF-mutated Melanoma that has not responded to
immunotherapy or a combination BRAF/MEK inhibitor) will be enrolled at the MTD in the Phase
1b study. Data collected from patients enrolled in each of these additional cohorts will be
used for to confirm safety, explore potential biomarkers, and evaluate potential signals of
activity when TP-0903 is administered to specific groups of heavily pretreated patients or
given in combination with immunotherapy or a tyrosine kinase inhibitor (TKI).

The study will investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary
anti-tumor activity profiles.

This is a phase 1a / 1b, first-in-human, open-label, dose-escalation, safety,
pharmacokinetics, and pharmacodynamic study of TP-0903 administered once daily for the first
21 out of 28 days.

There are 2 phases in this study. In Phase 1a (dose escalation), sequential cohorts of three
(3) patients will be treated with escalated doses until the MTD is established. In the
absence of dose-limiting toxicities (DLTs), the dose will be increased using a modified
Fibonacci dose escalation scheme.

Once the MTD has been established, dosing will change from BSA-dependent to a flat dose based
on the average of the dose administered in the MTD expansion safety cohort. Once the MTD has
been established, in Ph 1b (expansion), 5 additional cohorts of up to 20 patients each with
specific tumor types (up to 100 additional patients total) may be enrolled at the MTD dose
level to confirm safety, explore potential biomarkers, and evaluate potential signals of
activity when TP-0903 is administered to specific groups of heavily pretreated patients or
given in combination with immunotherapy or a tyrosine kinase inhibitor (TKI). Ten patients in
each of these 5 Expansion Cohorts will be required to consent to undergo pre- and post-dose
tumor biopsies. All patients who undergo these biopsies will comprise the 'Biopsy Cohorts'
(Phase 1b).

Patients who successfully complete a 4-week treatment cycle without evidence of significant
treatment-related toxicity or progressive disease will be permitted to continue to receive
treatment with the same dose and dosing schedule.

Inclusion Criteria:

To be eligible for participation in the study, patients must meet all of the following
inclusion criteria:

1. Patients enrolled in the Phase 1a study must:

1. Have a histologically confirmed diagnosis of advanced metastatic or progressive
solid tumor

2. Be refractory to, or intolerant of, established therapy known to provide clinical
benefit for their condition

2. Patients enrolled in the Phase 1b study must meet criteria for one of the following
tumor types:

1. Have tumors that have progressed after achieving a best documented response of at
least stable disease (ie, SD, PR, or CR documented per iRECIST following at least
2 cycles (8 weeks) of immunotherapy and are felt to be appropriate for this type
of treatment*

2. Have EGFR+ NSCLC and have demonstrated recent progression following a best
documented response of at least stable disease (ie, SD, PR, or CR documented per
per RECIST v1.1 on ≤2 lines of oral TKIs and are felt to be appropriate for this
type of treatment* Prior chemotherapy ± immunotherapy is allowed as long as the
patient is clearly demonstrating current progression on an EGFR TKI.

3. Have BRAF-, KRAS-, or NRAS-mutated CRC for whom there is no standard therapy
remaining

4. Have persistent/recurrent ovarian cancer who would be platinum refractory/
resistant and have had any number of lines of prior therapy

5. Have BRAF-mutated melanoma that has not responded to immunotherapy or a
combination BRAF/MEK inhibitor

3. Have one or more tumors measurable or evaluable as outlined by modified RECIST v1.1 or
iRECIST

4. Have an Eastern Cooperative Oncology Group (ECOG) (World Health Organization [WHO])
performance of ≤1

5. Have a life expectancy ≥3 months

6. Be ≥18 years of age

7. Have a negative pregnancy test (if female of childbearing potential)

8. Have acceptable liver function:

1. Bilirubin ≤1.5x upper limit of normal (ULN)

*Patients receiving immunotherapy should have a bilirubin level <3.0x ULN.

2. Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and
alkaline phosphatase ≤2.5x upper limit of normal (ULN)

- If liver metastases are present, then ≤5x ULN is allowed.

- Patients receiving immunotherapy should have AST and ALT levels <5.0x ULN.

9. Have acceptable renal function:

a. Calculated creatinine clearance ≥30 mL/min

10. Have acceptable hematologic status:

1. Granulocyte ≥1500 cells/mm3

2. Platelet count ≥100,000 (plt/mm3)

3. Hemoglobin ≥9 g/dL

11. Have no clinically significant abnormalities on urinalysis

12. Have acceptable coagulation status:

1. Prothrombin time (PT) within 1.5x normal limits

2. Activated partial thromboplastin time (aPTT) within 1.5x normal limits

13. Be nonfertile or agree to use an adequate method of contraception. Sexually active
patients and their partners must use an effective method of contraception (hormonal or
barrier method of birth control; or abstinence) prior to study entry and for the
duration of study participation and for at least 30 days after the last study drug
dose (see Section 4.6.3). Should a woman become pregnant or suspect she is pregnant
while participating in this study, she should inform her treating physician
immediately.

14. Have read and signed the IRB-approved informed consent form prior to any study related
procedure. (In the event that the patient is re-screened for study participation or a
protocol amendment alters the care of an ongoing patient, a new informed consent form
must be signed.)

15. Patients enrolled in each of the five Expansion Cohorts must be willing to consider
pre-study and on-study biopsies, if safe and medically feasible, as determined by
local interventional radiology (3 to 5 core samples requested at each biopsy
timepoint)

Patients meeting any one of these exclusion criteria will be prohibited from participating
in this study:

1. Have New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial
infarction within the past 6 months prior to Day 1, unstable arrhythmia, or evidence
of ischemia on electrocardiogram (ECG) or during Cardiac Stress Testing within 14 days
prior to Day 1 (Appendix C)

2. Have a corrected QT interval (QTcF, Fridericia's method) of >450 msec in men and >470
msec in women

3. Have a seizure disorders requiring anticonvulsant therapy

4. Presence of symptomatic central nervous system metastatic disease or disease that
requires local therapy such as radiotherapy, surgery, or increasing dose of steroids
within 2 weeks prior to Day 1

5. Have severe chronic obstructive pulmonary disease with hypoxemia (defined as resting
O2 saturation of ≤88% breathing room air)

6. Have undergone major surgery, other than diagnostic surgery, within 2 weeks prior to
Day 1

7. Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy

8. Are pregnant or nursing

9. Received treatment with radiation therapy, surgery, chemotherapy, or investigational
therapy within 28 days or 5 half lives, whichever occurs first, prior to study entry
(6 weeks for nitrosoureas or Mitomycin C)

a. This exclusion criterion is not applicable for patients with EGFR+ NSCLC or
immunotherapy-resistant tumors who are enrolled in expansion cohorts at the MTD.

10. Are unwilling or unable to comply with procedures required in this protocol

11. Have known infection with human immunodeficiency virus (HIV), hepatitis B, or
hepatitis C. Patients with history of chronic hepatitis that is currently not active
are eligible

12. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other
conditions) that could compromise protocol objectives in the opinion of the
investigator and/or the sponsor

13. Are currently receiving any other investigational agent

14. Have exhibited allergic reactions to a similar structural compound, biological agent,
or formulation

15. Have undergone significant surgery to the gastrointestinal tract that could impair
absorption or that could result in short bowel syndrome with diarrhea due to
malabsorption

16. Have a history of severe adverse reaction (eg, hypersensitivity reaction, anaphylaxis)
to sulfonamides

17. Patients scheduled to receive immunotherapy or TKI regimens plus TP-0903 must not be
currently taking high-dose steroids (ie, physiologic dose approximately equivalent to
15 mg/day of prednisone)
We found this trial at
16
sites
7703 Floyd Curl Drive
San Antonio, Texas 78229
Principal Investigator: John Sarantopoulos, MD
Phone: 210-450-2872
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Jason Melear, MD
Phone: 512-421-4100
?
mi
from
Austin, TX
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Muhammad Beg, MD
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80291
Principal Investigator: Ross Camidge, MD, PhD
Phone: 720-848-0685
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Allen Cohn, MD
?
mi
from
Denver, CO
Click here to add this to my saved trials
Eugene, Oregon 97401
Principal Investigator: Marc Uemura, MD
?
mi
from
Eugene, OR
Click here to add this to my saved trials
8503 Arlington Boulevard
Fairfax, Virginia 22031
Principal Investigator: Alexander Spira, MD
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Fairway, Kansas 66205
Principal Investigator: Joaquina Baranda, MD
Phone: 913-588-6029
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Stephen Richey, MD
Phone: 817-850-2011
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Principal Investigator: YanYan Lou, MD
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Miami, Florida 33176
Principal Investigator: Miguel Villalona Calero, MD
Phone: 786-594-7585
?
mi
from
Miami, FL
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Jonathan Thompson, MD
Phone: 414-805-0261
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phoenix, Arizona 85054
Principal Investigator: Mahesh Seetharam, MD
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Alex Adjei, MD
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Scottsdale, Arizona 85258
Principal Investigator: Vivek Khemka, MD
Phone: 480-323-1339
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Donald Richards, MD
Phone: 903-579-9800
?
mi
from
Tyler, TX
Click here to add this to my saved trials